BAIC has notched up an exit after the aluminium alloy component provider went public in a $47.8m offering on the Shenzhen Stock Exchange.

Xiaomi is the second largest shareholder in Kingsoft's cloud services spinoff, which has filed to raise up to $100m on the Nasdaq Global Select Market.

Partners Healthcare and Medison Pharma-backed Keros Therapeutics floated at the top of its range and will look to advance its musculoskeletal disorder drug candidates.

The Pharamron-backed oncology drug developer floated at the top of its range while increasing the number of shares in the offering.

Medison Pharma and Partners Healthcare could be in line for exits after the haematological and musculoskeletal disorder therapy developer filed to raise $86.3m.

Pfizer and Lundbeck scored exits as blood-disease therapy developer Imara raised $75.2m, floating at the foot of its range.

The genetic therapy developer, which had raised $126m in funding from investors including Eli Lilly and Access Industries, added $32.4m to the offering.

Underwriters have exercised their over-allotment option in full, increasing the University of Pennsylvania-linked genetic medicine developer’s proceeds by $32.4m.

The Pharmaron-backed cancer therapy developer is targeting $100m in an initial public offering preceded by $162m in funding.

Novartis and Harel are among the investors set to exit the cancer therapy developer, which also counts Bristol-Myers Squibb as a shareholder.